09/07/2026
WEIGHT LOSS PEPTIDES: Three Generations. One Goal.
Weight loss injectable medications have advanced rapidly across three distinct generations, each targeting more hormonal pathways than the last. Semaglutide, a GLP-1 single agonist, was the breakthrough — delivering approximately 14.9% body weight loss over 68 weeks and remaining the only option with proven cardiovascular benefits. Tirzepatide added a second receptor, GIP, achieving up to 22.5% weight loss and outperforming semaglutide by 47% in a direct head-to-head trial. Retatrutide, currently in Phase 3 trials, activates three receptors — GLP-1, GIP, and glucagon — producing up to 28.7% body weight loss in the TRIUMPH-4 trial, alongside an unprecedented 86% reduction in liver fat at 48 weeks. Each generation brings stronger efficacy but also distinct safety signals: pancreatitis risk with semaglutide, gallbladder events with tirzepatide, and dysesthesia — an abnormal sensation of tingling or numbness — emerging with retatrutide. All three require regular monitoring of liver function, blood sugar, thyroid, and kidney markers throughout treatment.
This content is shared for educational purposes only and does not constitute medical advice.
What aspect of GLP-1 peptide development are you most closely following in your practice? 👇
